Linda Wu
Columbia University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Linda Wu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07433673 · Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)Columbia University · recruiting · Colon and Rectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:45 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- 96 citationsRCR 8.0
- Electronic Trigger-Based Intervention to Reduce Delays in Diagnostic Evaluation for Cancer: A Cluster Randomized Controlled Trial.J Clin Oncol · 201590 citationsRCR 3.3
- Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial.Cancer Epidemiol Biomarkers Prev · 200874 citationsRCR 1.9
- Multimedia education programme for patients with a stoma: effectiveness evaluation.J Adv Nurs · 201138 citationsRCR 1.8
- 28 citationsRCR 4.1
- 23 citationsRCR 1.5
- Laparoscopic surgery contributes more to nutritional and immunologic recovery than fast-track care in colorectal cancer.World J Surg Oncol · 201520 citationsRCR 0.8
- Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.Cancer Commun (Lond) · 202517 citationsRCR 2.7
- 5 citationsRCR 0.8